Axial Biotech uses genetic research and minimally invasive, motion preserving implants to advance the diagnosis and treatment of diseases and deformities of the human spine. The company is currently developing DNA-based pre-symptomatic and prognostic tests for common spinal conditions. In its initial product development initiative, Axial seeks to pinpoint the human genome associated with adolescent idiopathic scoliosis.
Axial’s founders have also developed five fusionless surgical devices that may expand the current treatable scoliosis patient population by a factor of ten. Axial intends to use its proprietary genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery and product development methodology to other spinal diseases.
Mr. Climaco has been involved with start-up ventures in various capacities for the last ten years. Before moving to Utah, Mr. Climaco served as director of programming and legal affairs for Quokka Sports, a venture-backed online media company that went public in 1999.